Overview

Maxigesic® IV Phase 3 Exposure Study

Status:
Completed
Trial end date:
2020-07-07
Target enrollment:
Participant gender:
Summary
The study aims to determine the tolerability of repeated doses of Maxigesic® IV over an extended period of exposure.
Phase:
Phase 3
Details
Lead Sponsor:
AFT Pharmaceuticals, Ltd.